Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Particle size selection device for use with the Turbohaler

M L Everard1, S G Devadason, P N Le Souef

  • 1Department of Respiratory Medicine, Princess Margaret Hospital for Children, Perth, Western Australia.

Thorax
|May 1, 1996
PubMed
Summary

A new chamber for the Turbohaler effectively reduces non-respirable drug particles, minimizing upper airway deposition. This device preserves the respirable dose, enhancing dry powder inhaler therapy and reducing side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Personal network inference identifies children at risk of recurrent wheezing and asthma.

The Journal of allergy and clinical immunology·2026
Same author

Current options in aerosolised drug therapy for children receiving respiratory support.

Anaesthesia·2017
Same author

Lower anti-echovirus antibody responses in children presenting to hospital with asthma exacerbations.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2015
Same author

Rhinovirus and the developing lung.

Paediatric respiratory reviews·2014
Same author

Impact of CD14 promoter variants on measles vaccine responses and vaccine failure in children from Australia and Mozambique.

Tissue antigens·2013
Same author

International consensus on (ICON) pediatric asthma.

Allergy·2012

Area of Science:

  • Pharmaceutical Sciences
  • Respiratory Medicine
  • Biomedical Engineering

Background:

  • Drug deposition in the upper airways from dry powder inhalers (DPIs) offers no therapeutic benefit and can cause side effects.
  • A novel chamber utilizing Turbohaler's centrifugal force aims to minimize upper airway drug deposition by removing large particles.

Purpose of the Study:

  • To evaluate an in vitro particle size selection device for the Turbohaler.
  • To determine if the chamber reduces coarse particle dose without impacting the respirable dose.

Main Methods:

  • Modified a 200 mcg Turbohaler with a small volume chamber.
  • Assessed particle size distribution using a multi-stage liquid impinger (60 L/min flow rate).
  • Quantified drug dose on each impinger stage via ultraviolet spectrophotometry.

Related Experiment Videos

Main Results:

  • The chamber significantly reduced the dose of non-respirable particles (stages 1+2) from 52.2 to 29.6 mcg/actuation.
  • The respirable dose (particles < 6.8 microns) remained unaffected, with 91.1 mcg for standard Turbohaler vs. 82.4 mcg with the chamber.
  • No significant difference in respirable dose was observed between the standard Turbohaler and the Turbohaler with the chamber.

Conclusions:

  • An effective particle size selection device for the Turbohaler has been developed.
  • The device successfully reduces non-respirable particles while maintaining the respirable drug dose.
  • Similar devices may be feasible for other dry powder inhalers with device-specific design modifications.